Objectif Chronic hepatitis B virus (HBV) infection affects 350 million people worldwide and 25-30% of these individuals will die as a result of their infection mainly as a results of hepatocellular carcinoma HCC. Liver cirrhosis, high viral load and dietary exposure to aflatoxin are recognised as risk factors for hepatocellular carcinoma amongst HBV carriers. However, these variables do not account for all cases of HCC and decompensated cirrhosis is rarely ever seen in West Africa suggesting that advanced liver fibrosis may not be an important risk factor in this population. A large case control study on HCC will be used to evaluate the importance of liver fibrosis and other established risk factors in West Africa and to explore other potential oncogenic determinants. The case-control study will generate serum, urine and DNA samples for proteomic, metabonomic and genomic analysis to identify biomarkers and aetiological agents for HCC.Effective treatment for HBV infection is now available in the developed world but treatment programmes have not been developed for resource poor settings even though some of the effective medication is now available at low cost for HIV management. A trial of HBV treatment in a group of carefully selected high risk patients will be conducted to demonstrate that the incidence of HCC can be reduced in this population as has been observed in Asian patients. The treatment trial will also be used to evaluate the efficacy of screening by ultrasound for early tumours which can be treated with percutaneous alcohol injection.This comprehensive programme therefore aims to reveal novel aetiological factors for HCC, identify and evaluate biomarkers and demonstrate the efficacy of selective antiviral therapy to prevent HCC Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health scienceshealth sciencesinfectious diseasesDNA viruseshepatitis Bmedical and health scienceshealth sciencesinfectious diseasesRNA virusesHIVmedical and health sciencesclinical medicineoncologymedical and health sciencesclinical medicinehepatology Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Thème(s) HEALTH.2010.2.4.1-4 - Infectious agents and cancer in Africa Appel à propositions FP7-AFRICA-2010 Voir d’autres projets de cet appel Régime de financement CP-FP-SICA - Small/medium-scale focused research project for specific cooperation actions dedicated to international cooperation partner countries(SICA) Coordinateur IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE Contribution de l’UE € 642 000,00 Adresse SOUTH KENSINGTON CAMPUS EXHIBITION ROAD SW7 2AZ LONDON Royaume-Uni Voir sur la carte Région London Inner London — West Westminster Type d’activité Higher or Secondary Education Establishments Contact administratif Tatjana Palalic (Ms.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Participants (7) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire MEDICAL RESEARCH COUNCIL Royaume-Uni Contribution de l’UE € 1 105 300,00 Adresse 20 Park Crescent W1B 1AL LONDON Voir sur la carte Type d’activité Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments) Contact administratif Tumani Corrah (Prof.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER France Contribution de l’UE € 236 000,00 Adresse 25 AVENUE TONY GARNIER 69007 Lyon 7eme Voir sur la carte Région Auvergne-Rhône-Alpes Rhône-Alpes Rhône Type d’activité Research Organisations Contact administratif Olaf Kelm (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE France Contribution de l’UE € 158 000,00 Adresse RUE DE TOLBIAC 101 75654 Paris Voir sur la carte Région Ile-de-France Ile-de-France Paris Type d’activité Research Organisations Contact administratif Hiba Vergnaud (Ms.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée JOS UNIVERSITY TEACHING HOSPITAL Nigeria Contribution de l’UE € 189 500,00 Adresse MURTALA MOHAMMED WAY PLATEAU STATE 930001 JOS Voir sur la carte Type d’activité Higher or Secondary Education Establishments Contact administratif Edith Okeke (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée UNIVERSITE CHEIKH ANTA DIOP DE DAKAR Sénégal Contribution de l’UE € 324 000,00 Adresse Avenue Martin Luther King - Dakar Fann Voir sur la carte Type d’activité Higher or Secondary Education Establishments Contact administratif Souleymane Mboup (Prof.) Liens Contacter l’organisation Opens in new window Coût total Aucune donnée Ministry of Health and Social Welfare Gambie Contribution de l’UE € 137 200,00 Adresse The quadrangle, Banjul Banjul Voir sur la carte Type d’activité Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments) Contact administratif Makie Taal (Dr.) Liens Contacter l’organisation Opens in new window Coût total Aucune donnée XEPTAGEN SPA Italie Contribution de l’UE € 208 000,00 Adresse Via delle Industrie 9 30175 VENEZIA Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Giorgio Fassina (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée